publication date: May 31, 2011
|
author/source: Protagen
Protagen AG, a specialist in
in-vitro diagnostics and GMP-compliant protein analysis
announced
today that they will be using the
UNIarray®
Platform to help discover biomarkers in relapsing remitting multiple sclerosis
for Biogen Idec, Inc. Under the terms of the agreement, Protagen will apply its
UNIarray
® technology platform and expertise in autoantibody research
to support retrospective analysis of samples from a Biogen Idec clinical trial
for the purpose of finding predictive and response biomarkers associated with
multiple sclerosis (MS) therapy.
"There is an
acute need to discover possible response and non-response biomarkers in MS
using genomic and proteomic level markers," said Dr. Peter Schulz-Knappe, CSO
of Protagen AG. "Autoantibody signatures play an increasingly important role as
a technology platform that could be used to identify patients for optimized
treatment efficacy and to monitor disease progression."
"Pharmaceutical
companies recognize more and more the importance of autoantibody signatures for
drug development, and Protagen provides the right technology and unique
expertise for collaborations in this area", said Dr. Stefan Müllner, CEO.
Background:
UNIarray
® is a unique technology platform for the development of
novel diagnostics based on indication specific autoantibody patterns in patient
sera. These indication specific autoantibody patterns were already proven to be
present in several autoimmune diseases, but also in cancer and
neurodegenerative disorders. The systematic and indication-specific
determination of autoantibody patterns will serve as a powerful basis to
address hitherto unmet diagnostic needs. UNIarray
® serves as
platform for the development of product specific companion diagnostics and
patient stratification tools for clinical studies.
About Protagen AG - www.protagen.de
Protagen AG is an international leading specialist in the fields of
in-vitro
diagnostics and GMP-compliant protein analysis. The innovations of Protagen are
UNIarray
®, a technology platform for the development of novel serum
based diagnostics, as well as UNIchip
®, a versatile product family
of protein microarrays for faster development of antibodies.
Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!
Request your free copies HERE
Popular this Month
Top 10 most popular articles this month
Today's Picks
Looking for a Supplier?
Search by company or by product
Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.
Lab Bulletin is published by newleaf marketing communications ltd.